{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:28:00Z","timestamp":1775759280518,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013337","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000}}],"reference-count":376,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013337.pub2","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T15:37:25Z","timestamp":1664811445000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacological interventions for prevention of weight gain in people with schizophrenia"],"prefix":"10.1002","volume":"2023","author":[{"given":"Sri Mahavir","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Stogios","sequence":"additional","affiliation":[{"name":"Schizophrenia Division; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra A","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan T","family":"Lockwood","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus J","family":"Duncan","sequence":"additional","affiliation":[{"name":"School of Kinesiology; University of British Columbia; Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Cohn","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie H","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Women's College Hospital, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy E J","family":"Faulkner","sequence":"additional","affiliation":[{"name":"School of Kinesiology; University of British Columbia; Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hahn","sequence":"additional","affiliation":[{"name":"Complex Care and Recovery; Centre for Addiction and Mental Health, University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0001|cit1","first-page":"1130","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman","year":"2008","journal-title":"Saudi Medical Journal"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0924-9338(11)73417-4","article-title":"Is metformin effective to prevent weight gain associated with risperidone?","volume":"26 Suppl 1","author":"Farshidfar","year":"2011","journal-title":"European Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/070674370605100310","article-title":"Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial","volume":"51","author":"Baptista","year":"2006","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0b013e32801182e6","article-title":"Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin","volume":"22","author":"Baptista","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0924-977X(01)80355-2","article-title":"Nizatidine may ameliorate weight gain during olanzapine treatment","volume":"11","author":"Breier","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0006|cit6","unstructured":"Breier AF Tanaka Y Roychowdhury S Nizatidine ameliorates olanzapine treatment-related weight gain 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0007|cit7","unstructured":"Breier AF Tanaka Y Roychowdhury S Nizatidine ameliorates olanzapine treatment-related weight gain 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0924-977X(02)00127-X","article-title":"Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial","volume":"13","author":"Cavazzoni","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study","volume":"177","author":"Correll","year":"2020","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Kim J Yim S Nam J A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland Elsevier Science Bv 2006 86","DOI":"10.1016\/j.schres.2005.10.001"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Kim JH Yim S Nam J A 12-week open label trial of topiramate for limiting weight gain during olanzapine treatment in patients with schizophrenia 159th annual meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006","DOI":"10.1016\/j.schres.2005.10.001"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2005.10.001","article-title":"A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia","volume":"82","author":"Kim","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"06","key":"10.1002\/14651858.CD013337.pub2-BIB0013|cit13","first-page":"665","article-title":"Topiramate combined olanzapine prevention second-generation antipsychotic-induced body weight and metabolic dysfunction","volume":"23","author":"Liu","year":"2011","journal-title":"Contemporary Nurse (Specialist Edition)"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0014|cit14","unstructured":"An assessment of effects of melatonin on metabolic effects of olanzapine in patients with schizophrenia https:\/\/www.irct.ir\/trial\/7480"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpsychires.2014.02.013","article-title":"Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study","volume":"53","author":"Modabbernia","year":"2014","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0016|cit16","unstructured":"Melatonin for prevention of metabolic side effects of olanzapine https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01593774"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2010.02.001","article-title":"Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial","volume":"118","author":"Narula","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S0924-977X(02)80464-3","article-title":"Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"12 Suppl 3","author":"Poyurovsky","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1176\/appi.ajp.159.6.1058","article-title":"Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition","volume":"159","author":"Poyurovsky","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.160.2.297","article-title":"Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study","volume":"160","author":"Poyurovsky","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0021|cit21","first-page":"S171","article-title":"Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study","volume":"5 Suppl 1","author":"Poyurovsky","year":"2002","journal-title":"International journal of neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0022|cit22","first-page":"S171","article-title":"Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study","volume":"5 Suppl 1","author":"Poyurovsky","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euroneuro.2003.10.004","article-title":"The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study","volume":"14","author":"Poyurovsky","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Poyurovsky M Fuchs C Pashinian A Levi A Faragian S Maayan R Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study 62nd Annual Scientific Meeting of the Society of Biological Psychiatry 2007 129","DOI":"10.1007\/s00213-007-0731-1"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","article-title":"Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study","volume":"192","author":"Poyurovsky","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0026|cit26","unstructured":"Poyurovsky M Maayan R Gil-Ad I Weizman A Weizman R Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination","volume":"226","author":"Poyurovsky","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0028|cit28","unstructured":"Metformin for the prevention of the metabolic side-effects of zyprexa http:\/\/clinicaltrials.gov\/show\/NCT00682448"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/JCP.0000000000000469","article-title":"A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population","volume":"36","author":"Rado","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0030|cit30","unstructured":"Sun J Ranitidine prevention and treatment of olanzapine-induced weight gain and glucose metabolism disorders Chinese Journal of Nervous and Mental Disorders 2007 33 9 560 2"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0031|cit31","first-page":"200","article-title":"Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study","volume":"8","author":"Vishnupriya","year":"2016","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1176\/appi.ajp.2008.165.4.540b","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study: correction","volume":"165","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study","volume":"165","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"Art ID 143","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"13","author":"Adams","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Agahi M Akasheh N Ahmadvand A Akbari H Izadpanah F Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial Diabetes and Metabolic Syndrome 2018 12 1 9 15","DOI":"10.1016\/j.dsx.2017.08.004"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0036|cit36","unstructured":"Effect of melatonin in side effects of second-generation antipsychotic medications https:\/\/trialsearch.who.int\/?TrialID=IRCT2016051027832N1"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0037|cit37","first-page":"110","article-title":"Metformin in schizophrenia spectrum disorders and early co-morbid prediabetes\/diabetes: a double-blind randomized control trial","volume":"44 Suppl 1","author":"Agarwal","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1590\/S1516-44462006000400005","article-title":"Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine","volume":"28","author":"Assuncao","year":"2006","journal-title":"Revista Brasileira de Psiquiatria (Sao Paulo, Brazil : 1999)"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0039|cit39","unstructured":"Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00486005"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hup.514","article-title":"Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain","volume":"18","author":"Atmaca","year":"2003","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hup.477","article-title":"Nizatidine for the treatment of patients with quetiapine-induced weight gain","volume":"19","author":"Atmaca","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3371\/CSRP.5.1.3","article-title":"Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine","volume":"5","author":"Ball","year":"2011","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0043|cit43","unstructured":"Double-blind study of atomoxetine for weight management in patients taking olanzapine or clozapine https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00176436"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophrenia Research"},{"issue":"1-2","key":"10.1002\/14651858.CD013337.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0046|cit46","unstructured":"Uzcategui E EIFakih Y Rangel N Galeazzi T Baptista T Metformin plus sibutramine in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0028-1085438","article-title":"Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial","volume":"42","author":"Baptista","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0048|cit48","unstructured":"Barak N Betahistine safely mitigates olanzapine adverse: role of histamine receptors in weight gain and somnolence 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/JCP.0000000000000489","article-title":"A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain","volume":"36","author":"Barak","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0000000000000022","article-title":"Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia","volume":"29","author":"Biedermann","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD013337.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2010.02.410","article-title":"Sibutramine in the treatment of antipsychotic-induces weight gain: a randomized, placebo-controlled double-blind study","volume":"117","author":"Biedermann","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/JCP.0b013e31822bb573","article-title":"Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia","volume":"31","author":"Borba","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4088\/JCP.v63n0412","article-title":"Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment","volume":"63","author":"Borovicka","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0054|cit54","unstructured":"Bushe C Poole-Hoffmann V Lipkovich I Metabolic comparisons from a 6-month randomized trial of olanzapine and quetiapine in schizophrenia 62nd Annual Scientific Meeting of the Society of Biological Psychiatry San Diego, CA, USA Elsevier Science Inc 2007 255"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0269881108101783","article-title":"Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia","volume":"24","author":"Bushe","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0056|cit56","unstructured":"Bustillo JR Lauriello J Hammond R Keith S Treatment of weight-gain with fluoxetine in olanzapine-treated schizophrenic outpatients 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.npp.1300089","article-title":"Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients","volume":"28","author":"Bustillo","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD013337.pub2-BIB0058|cit58","first-page":"236","article-title":"Treatment of weight-gain with fluoxetine in olanzapine-treated schizophrenic outpatients","volume":"49","author":"Lauriello","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0059|cit59","unstructured":"Baptista T Carrizo E Fernandez V Sandia I Connell L Prieto D Metformin for body weight and metabolic control in patients with schizophrenia during long-term clozapine administration 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0060|cit60","unstructured":"Baptista TJ Fernandez E Carrizo E Fernandez V Sandia I Prieto D Polimorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","article-title":"Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study","volume":"113","author":"Carrizo","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2009.08.006","article-title":"Corrigendum to \"Extended release metfomin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study\" Schizophr. Res. 113 (1) (2009) 19-26 (DOI:10.1016\/j.schres.2009.05.007)","volume":"115","author":"Carrizo","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2010.06.001","article-title":"Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin","volume":"121","author":"Fernandez","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JCP.0b013e3182485871","article-title":"The sustained effects of aripiprazole-augmented clozapine treatment on the psychotic systems and metabolic profiles of patients with refractory schizophrenia","volume":"32","author":"Chang","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"04","key":"10.1002\/14651858.CD013337.pub2-BIB0065|cit65","first-page":"198","article-title":"Metformin combined behavioral intervention therapy of clozapine in the treatment of schizophrenia in patients with body weight, blood glucose, blood lipids","volume":"23","author":"Chen","year":"2010","journal-title":"Sichuan Mental Health"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.4088\/JCP.12m08186","article-title":"Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study","volume":"74","author":"Chen","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0067|cit67","unstructured":"Effects of adjunctive metformin on metabolic profiles in clozapine-treated schizophrenic patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01300637"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JCP.0000000000000386","article-title":"The relationships of obesity-related genetic variants with metabolic profiles and response to metformin in clozapine-treated patients with schizophrenia","volume":"35","author":"Chen","year":"2015","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e0168347","DOI":"10.1371\/journal.pone.0168347","article-title":"Effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: an exploratory twelve-week randomized, double-blind, placebo-controlled study","volume":"11","author":"Chiu","year":"2016","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0070|cit70","unstructured":"Adjunctive low-dose metformin in patients with schizophrenia and metabolic abnormalities https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02751307"},{"issue":"16","key":"10.1002\/14651858.CD013337.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD013337.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2013.13060771","article-title":"Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?","volume":"170","author":"Correll","year":"2013","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial","volume":"19","author":"Correll","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0074|cit74","unstructured":"A clinical trial to study the effects of metformin in prevention of olanzapine induced weight gain, type 2 diabetes mellitus and lipid abnormalities in patients with schizophrenia https:\/\/trialsearch.who.int\/?TrialID=CTRI\/2013\/05\/003685"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0075|cit75","first-page":"409","article-title":"The effects of metformin on obesity, glucose and lipid metabolism caused by antipsychotic drugs in schizophrenia patients","volume":"24","author":"Dai","year":"2014","journal-title":"Ch\u00e1ng Zh\u00ec Y\u012b Xu\u00e9 Yu\u00e0n Xu\u00e9 B\u00e0o"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0076|cit76","first-page":"34","article-title":"The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia","volume":"114","author":"Danilov","year":"2014","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0077|cit77","unstructured":"Deberdt W Cavazzoni PA Trzaskoma Q Bymaster FP Winokur A Floris M Amantadine for weight gain in olanzapine-treated patients 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Deberdt W Trzaskoma Q Carlson C Bymaster F Winokur A Floris M Amantadine for weight gain in olanzapine-treated patients Thematic conference of the World Psychiatric Association on \"Treatments in psychiatry: an update\"; 2004 Nov 10-13; Florence, Italy 2004","DOI":"10.1016\/j.euroneuro.2004.03.005"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0079|cit79","first-page":"182","article-title":"Amantadine for weight gain in olanzapine-treated patients","volume":"67","author":"Deberdt","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","article-title":"Amantadine for weight gain associated with olanzapine treatment","volume":"15","author":"Deberdt","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4088\/JCP.v67n1208","article-title":"Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder","volume":"67","author":"De Hert","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/0269881117691447","article-title":"Corrigendum","volume":"31","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/0269881115613519","article-title":"Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: a double blind, randomized, placebo controlled study","volume":"29","author":"Silva","year":"2015","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0269881117693736","article-title":"Metformin for antipsychotic-induced weight gain: statistical curiosities","volume":"31","author":"Pinto","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00002826-200307000-00010","article-title":"Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia","volume":"26","author":"Deutsch","year":"2003","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0086|cit86","first-page":"25","article-title":"The therapeutic effects of ling gui zhu gan tang mixture in 50 psychotic patients with obesity induced by the psychoactive drugs","volume":"25","author":"Ding","year":"2005","journal-title":"Journal of Traditional Chinese Medicine \/ Chung i Tsa Chih Ying Wen Pan"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/jcp.0b013e31814b98e5","article-title":"Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation","volume":"5","author":"Egger","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1093\/schbul\/sbz021.268","article-title":"Effects of the glucagon-like peptide-1 receptor agonist exenatide on bone status in obese, non-diabetic, antipsychotic-treated schizophrenia spectrum patients","volume":"45 Suppl 2","author":"Eriksson","year":"2019","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0034-1382001","article-title":"Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study","volume":"47","author":"Fadai","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/2008-2231-20-43","article-title":"Role of omega-3-fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: A randomized double-blind placebo-controlled trial","volume":"20","author":"Faghihi","year":"2012","journal-title":"DARU, Journal of Pharmaceutical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/acps.12009","article-title":"Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia","volume":"127","author":"Fan","year":"2013","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0092|cit92","unstructured":"Aripiprazole for clozapine associated medical morbidity https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00345033"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0093|cit93","unstructured":"Efficacy of aripiprazole adjunctive treatment on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with clozapine. A randomized, double-blind, placebo-controlled trial https:\/\/trialsearch.who.int\/?TrialID=CTRI\/2013\/02\/003397"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S0924-977X(08)70660-6","article-title":"Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine","volume":"18","author":"Fleischhacker","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0095|cit95","first-page":"PO1.31","article-title":"Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response to clozapine","volume":"8 Suppl 1","author":"Fleischhacker","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.eurpsy.2008.01.784","article-title":"Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study","volume":"23 Suppl 2","author":"Fleischhacker","year":"2008","journal-title":"European Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0098|cit98","unstructured":"A multicenter, comparative, randomized, double-blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00300846"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2013.03.021","article-title":"The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"147","author":"Ghanizadeh","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1192\/bjp.153.2.208","article-title":"A clinical trial of the efficacy and acceptability of D-fenluramine in the treatment on neuroleptic-induced obesity","volume":"153","author":"Goodall","year":"1988","journal-title":"British Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD013337.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/appi.ajp.162.9.1744","article-title":"Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine","volume":"162","author":"Graham","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0102|cit102","first-page":"184","article-title":"Double blind placebo controlled investigation of amantadine for weight loss in subjects who have gained weight during treatment with olanzapine","volume":"67","author":"Graham","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0103|cit103","unstructured":"Double blind placebo controlled investigation of amantadine for retarding weight gain in first episode adult psychotic subjects beginning therapy with olanzapine https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00287352"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0104|cit104","unstructured":"Hadley S Metformin for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0105|cit105","first-page":"364","article-title":"Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder","volume":"20","author":"Hebrani","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0106|cit106","first-page":"160","article-title":"Molindone and weight loss","volume":"54","author":"Heikkinen","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"162","author":"Henderson","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0108|cit108","first-page":"152","article-title":"A placebo-controlled trial of sibutramine added to patients with olanzapine-induced weight gain","volume":"5 Suppl 1","author":"Henderson","year":"2004","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0109|cit109","unstructured":"Henderson DC Nguyen D Daley TB Louie P Burba C Copeland P Double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA 2004"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0447.2006.00855.x","article-title":"A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain","volume":"115","author":"Henderson","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1600-0447.2008.01325.x","article-title":"A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia","volume":"119","author":"Henderson","year":"2009","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0112|cit112","unstructured":"A double-blind, placebo-controlled trial of rosiglitazone for clozapine induced glucose metabolism impairment: Bergman's minimal model analysis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00337350"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0114|cit114","unstructured":"A placebo-controlled, cross-over trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00351936"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2011.04.009","article-title":"Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia","volume":"130","author":"Henderson","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0116|cit116","unstructured":"Hoffmann V Case M Jacobson J Algorithms including amantadine, metformin and zonisamide for mitigation of weight gain during olanzapine treatment in outpatients with schizophrenia 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4088\/JCP.09m05580","article-title":"Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study","volume":"73","author":"Hoffmann","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0118|cit118","unstructured":"The assessment of the safety, efficacy, and practicality of an algorithm including amantadine, metformin and zonisamide for the prevention of olanzapine-associated weight gain in outpatients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00401973"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0119|cit119","first-page":"363","article-title":"The stabilizing effect of dehydroepiandosterone on clinical paramters of metabolic syndrome in patients with schizophrenia treated with olanzapine- a randomized, double-blind trial","volume":"49","author":"Holka-Pokorska","year":"2015","journal-title":"Psychiatriapolska"},{"issue":"11","key":"10.1002\/14651858.CD013337.pub2-BIB0120|cit120","first-page":"1610","article-title":"Efficacy of metformin on serum homocysteine level in schizophrenia patients with olanzapine \uff0d induced weight gain","volume":"21","author":"Hu X\uff0cOuyang","year":"2013","journal-title":"China Journal of Health Psychology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0121|cit121","unstructured":"Betahistine and weight- related and metabolic measures in schizophrenic patients treated with olanzapin or risperidone https:\/\/www.irct.ir\/trial\/44644"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/dom.13204","article-title":"Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"20","author":"Ebdrup","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fpsyt.2018.00781","article-title":"Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density","volume":"9","author":"Eriksson","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1093\/schbul\/sbz021.268","article-title":"Effects of the glucagon-like peptide-1 receptor agonist exenatide on bone status in obese, non-diabetic, antipsychotic-treated schizophrenia spectrum patients","volume":"45","author":"Eriksson","year":"2019","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ishoy","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Ishoy PL Fagerlund B Broberg BV Bak N Knop FK Glenthoj BY No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotictreated, obese patients with schizophrenia Dansk Psykiatrisk Selskabs Arsmode; 2-4 February 2017; Kolding, Denmark 2017","DOI":"10.1111\/acps.12711"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"e004158","DOI":"10.1136\/bmjopen-2013-004158","article-title":"Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol","volume":"4","author":"Ishoy","year":"2014","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Ishoy PL Knop FK Broberg BV Bak N Andersen UB Jorgensen NR Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial Dansk Psykiatrisk Selskabs Arsmode; 2-4 February 2017; Kolding, Denmark 2017","DOI":"10.1111\/dom.12795"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ishoy","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/schbul\/sbx024.017","article-title":"GLP-1 receptor agonist treatment in schizophrenia patients with obesity","volume":"43","author":"Ishoy","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0131|cit131","first-page":"S402","article-title":"Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist: an investigator initiated prospective, randomized, placebo-controlled, double-blinded intervention study (the TAO study)","volume":"41","author":"Ishoy","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0132|cit132","unstructured":"Treatment of antipsychotic-associated obesity with a GLP-1 analogue https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01794429"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0133|cit133","first-page":"55","article-title":"The effects of topiramate on weight gain in patients with schizophrenia: a double-blind randomized placebo-controlled clinical trial","volume":"8","author":"Jamilian","year":"2018","journal-title":"Journal of Pioneering Medical Sciences"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0134|cit134","first-page":"24","article-title":"Metformin and impaired glucose tolerance in overweight persons with schizophrenia","volume":"37 Suppl 1","author":"Ballon","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD013337.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder","volume":"170","author":"Jarskog","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0136|cit136","unstructured":"Lieberman J Jarskog LF Hamer R Catellier D Stewart D LaVange L Metformin for obesity and metabolic abnormalities in schizophrenia 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0137|cit137","first-page":"S225","article-title":"Metformin for obesity and metabolic abnormalities in schizophrenia","volume":"35","author":"Lieberman","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0138|cit138","unstructured":"The use of metformin in the treatment of antipsychotic-induced weight gain in schizophrenia (The METS Study) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00816907"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0139|cit139","first-page":"S41","article-title":"Effect of metformin on weight in patients with schizophrenia with impaired fasting glucose","volume":"38","author":"Stroup","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Jarskog L Stroup TS Metformin and 5-HT2C agonist lorcaserin for weight loss in schizophrenia Biological Psychiatry 2018 83 9 Suppl 1 S105 6","DOI":"10.1016\/j.biopsych.2018.02.280"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0141|cit141","unstructured":"Metformin and lorcaserin for weight loss in schizophrenia https:\/\/clinicaltrials.gov\/"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0142|cit142","first-page":"295","article-title":"Efficacy of behavioral intervention adjunctive to rosuvastatin for antipsychotic-induced metabolic syndrome","volume":"50","author":"Jiang","year":"2017","journal-title":"Chinese Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/YIC.0b013e32835b08d2","article-title":"In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation","volume":"28","author":"Chukhin","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0144|cit144","unstructured":"Orlistat therapy in clozapine- and olanzapine-treated patients who are overweight or obese https:\/\/www.isrctn.com\/ISRCTN65731856"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0145|cit145","unstructured":"Joffe G Rasaoeo PK A double-blind, placebo controlled, randomized, 16-week trial of orlistat in the prevention and management of clozapine and olanzapine-induced weight gain in 80 patients with psychotic Stanley Foundation Research Programs 2002"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4088\/JCP.09m05283yel","article-title":"Orlistat in clozapine- or olanzapine- treated patients with overweight or obesity: a 16-week open label extension phase and both phases of a randomized controlled trial","volume":"72","author":"Tchoukhine","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fpsyt.2018.00620","article-title":"Effect of betahistine and metformin on antipsychotic-induced weight gain: an analysis of two clinical trials","volume":"9","author":"Kang","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0149|cit149","unstructured":"Maayan L Betahistine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0150|cit150","unstructured":"To examine the effect of betahistine on antipsychotic induced weight gain in adolescents https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00709202"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ebm.13.5.146","article-title":"Metformin plus a lifestyle intervention was more effective than either alone for antipsychotic-induced weight gain: commentary","volume":"13","author":"Vaz-Leal","year":"2008","journal-title":"Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0920-9964(12)70279-7","article-title":"Metformin for treatment of atypical antipsychotic-induced weight gain and endocrinological side effects in patients with first episode schizophrenia: results from randomized, double blind, placebo-controlled study","volume":"136","author":"Wu","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0153|cit153","first-page":"185","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"299","author":"Jin","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0154|cit154","first-page":"195","article-title":"Efficacy of behavioral intervention therapy and metformin in the treatment of atypical antipsychotics-induced metabolic syndrome","volume":"22","author":"Zhu","year":"2009","journal-title":"Archives of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia","volume":"31","author":"Kelly","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0156|cit156","first-page":"41","article-title":"Effect of metformin in reduction of anti-psychotic medication induced weight gain in schizophrenia","volume":"34","author":"Khan","year":"2020","journal-title":"Journal of Postgraduate Medical Institute"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0157|cit157","unstructured":"Kim SI Sung YM Paik KW Yun KW Kim YC Lim W The efficacy of topiramate for weight loss and psychiatric symptom severity in overweight or obese patients maintained on atypical antipsychotics 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/YIC.0000000000000132","article-title":"Adjunctive alpha-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study","volume":"31","author":"Kim","year":"2016","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0159|cit159","unstructured":"Cottingham EM Morrison JA Klein DJ Barton BA A randomized, double-blind placebo-controlled trial of metformin (glucophage\u00ae) for weight-gain associated with atypical antipsychotics in children and adolescents 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0161|cit161","first-page":"32","article-title":"Metformin treatment of weight gain associated with antipsychotic drug therapy","volume":"11 Suppl 1","author":"Klein","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.wnf.0000172994.56028.c3","article-title":"Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain","volume":"28","author":"Ko","year":"2005","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4088\/JCP.v67n0405","article-title":"Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial","volume":"67","author":"Kwon","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0164|cit164","unstructured":"Assessment of a weight management program for weight gain in patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00485823"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0165|cit165","unstructured":"The assessment of a weight management program for treatment-emergent weight gain in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during olanzapine therapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00485823"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"e004227","DOI":"10.1136\/bmjopen-2013-004227","article-title":"Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial","volume":"4","author":"Larsen","year":"2014","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0169|cit169","first-page":"A33","article-title":"The GLP-1 analog liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine","volume":"66 Suppl 1","author":"Vedtofte","year":"2017","journal-title":"Diabetes"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2013.01.034","article-title":"No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia","volume":"146","author":"Li","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0171|cit171","unstructured":"Intranasal insulin treatment in patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00575666"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0172|cit172","unstructured":"Effects and mechanism of T-cell subgroup imbalance on antipsychotic drug-induced obesity http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=34285"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpsychires.2020.04.009","article-title":"A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: a randomized controlled trial","volume":"126","author":"Li","year":"2020","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0174|cit174","first-page":"293","article-title":"Chlorpromazine, clozapine, risperidone on glucose metabolism in patients with first-episode schizophrenia, the effects of blood lipids and weight","volume":"30","author":"W\u00fa","year":"2004","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2018.00181","article-title":"Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia","volume":"9","author":"Lyu","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0177|cit177","unstructured":"Naltrexone and bupropion combination on obese, smoking patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02736474"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0178|cit178","first-page":"12","article-title":"The GLP-1 analog liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine","volume":"29","author":"Larsen","year":"2017","journal-title":"Acta Neuropsychiatrica"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"113670","DOI":"10.1016\/j.psychres.2020.113670","article-title":"Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial","volume":"296","author":"Maagensen","year":"2021","journal-title":"Psychiatry Research"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/JCP.0b013e3182488758","article-title":"A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain","volume":"32","author":"McElroy","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0182|cit182","unstructured":"Efficacy of ranitidine in olanzapine induced weight gain: a dose response study http:\/\/www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=7044&EncHid=&modid=&compid=%27,%277044det%27"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/eip.12205","article-title":"Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study","volume":"10","author":"Mehta","year":"2014","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajp.2014.08.005","article-title":"Role of ranitidine in negative symptoms of schizophrenia--an open label study","volume":"12","author":"Mehta","year":"2014","journal-title":"Asian Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0185|cit185","first-page":"95","article-title":"Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients","volume":"193","author":"Modell","year":"1965","journal-title":"Journal of American Medical Assosiation"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0186|cit186","first-page":"A17","article-title":"The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170)","volume":"22","author":"Millar","year":"2008","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.schres.2010.12.011","article-title":"Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","volume":"123","author":"Muscatello","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0269881110372548","article-title":"Topiramate augumentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","volume":"25","author":"Muscatello","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0189|cit189","unstructured":"The assessment of sibutramine for the treatment of olanzapine-associated weight gain in subjects with schizophrenia, schizophreniform disorder, schizoaffective disorder, and bipolar I disorder https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00044187"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0190|cit190","unstructured":"A double-blind, randomised, parallel-group comparison of ethyl-eicosapentaenoic acid (ethyl-epa) versus placebo as add-on medication in patients with established tardive dyskinesia https:\/\/clinicaltrials.gov\/show\/NCT00114595"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0191|cit191","unstructured":"Nicotine replacement therapy added to cognitive behavioral therapy for smoking cessation in patients with major mental illness https:\/\/clinicaltrials.gov\/show\/NCT00320723"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0192|cit192","unstructured":"A placebo-controlled trial of org 24448 (ampakine) added to atypical antipsychotics in patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00425815"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0193|cit193","unstructured":"Melatonin metabolism abnormality in patients with schizophrenia or schizoaffective disorder treated with olanzapine and melatonin dose finding for the correction of the metabolic abnormality https:\/\/clinicaltrials.gov\/show\/NCT00512070"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0194|cit194","unstructured":"Cardio risk of acute schizophrenia olanzapine Duke (CRASOD) https:\/\/clinicaltrials.gov\/show\/NCT00672464"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0195|cit195","unstructured":"A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003:GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated with olanzapine or other antipsychotic(s) treatment in subjects with schizophrenia or other non-affective psychosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01491490"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0196|cit196","unstructured":"A pilot study of naltrexone \u2013 bupropion combination versus placebo combined with bupropion for weight loss in comorbid schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03132571"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WNF.0000000000000188","article-title":"A pilot study of randomized, head-to-head of metformin versus topiramate in obese people with schizophrenia","volume":"39","author":"Peng","year":"2016","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0199|cit199","first-page":"826","article-title":"Metformin addition therapy attenuates serum levels of leptin in schizophrenia with olanzapine-induced weight gain","volume":"22","author":"Pan","year":"2014","journal-title":"China Journal of Health Psychology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0200|cit200","unstructured":"Radulovic L Weiden PJ Allison DB Camille C Sibutramine treatment of obesity in schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"639391","DOI":"10.1155\/2013\/639391","article-title":"The effect of ranitidine on olanzapine-induced weight gain","volume":"2013","author":"Ranjbar","year":"2013","journal-title":"Biomedical Research International"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1753-2000-7-31","article-title":"Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods","volume":"7","author":"Reeves","year":"2013","journal-title":"Child and Adolescent Psychiatry and Mental Health"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/S0924-977X(17)31686-3","article-title":"A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophrenia, schizophreniform, or bipolar I disorder","volume":"27 Suppl 4","author":"David","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0204|cit204","unstructured":"Study to evaluate the efficacy of ALKS 3831 on body weight in young adults who have been recently diagnosed with schizophrenia, schizophreniform or bipolar I disorder https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2017-000497-11-AT"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0205|cit205","unstructured":"Study to evaluate the efficacy of ALKS 3831 on body weight in young adults who have been recently diagnosed with schizophrenia, schizophreniform, or bipolar I disorder https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03187769"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1093\/schbul\/sby018.1013","article-title":"A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophreniform, schizophrenia, or bipolar I disorder","volume":"44 Suppl 1","author":"Simmons","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0207|cit207","unstructured":"A pilot study on the effect of once weekly exenatide compared to treatment as usual for weight loss and glycaemic control in schizophrenia patients with obesity and diabetes https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=368512"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0208|cit208","first-page":"67","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial","volume":"1","author":"Mayfield","year":"2015","journal-title":"BJ Psych Open"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1093\/schbul\/sbx023.046","article-title":"RCT of exenatide for clozapine-associated obesity","volume":"43","author":"Siskind","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/schbul\/sby016.436","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial","volume":"44 Suppl 1","author":"Siskind","year":"2018","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0211|cit211","first-page":"68","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide (codex) in adults with schizophrenia","volume":"51 Suppl 1","author":"Siskind","year":"2017","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1093\/schbul\/sbaa029.604","article-title":"12-month follow up of metabolic measures following a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (Codex)","volume":"46","author":"Siskind","year":"2020","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.10.023","article-title":"Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study","volume":"143","author":"Smith","year":"2013","journal-title":"Schizophrenia Research"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s00213-018-5079-1","article-title":"Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study","volume":"235","author":"Smith","year":"2018","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psyneuen.2006.11.002","article-title":"Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial","volume":"32","author":"Strous","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.euroneuro.2019.09.160","article-title":"Adjunctive treatment of aripiprazole to olanzapine for weight reduction in patients with schizophrenia","volume":"29","author":"Sulejmanpasic","year":"2019","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.euroneuro.2019.09.159","article-title":"Olanzapine augmented with aripiprazole in treatment-resistant schizophrenia","volume":"29","author":"Sulejmanpasic","year":"2019","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0220|cit220","first-page":"84","article-title":"Effect of topiramate on drug associated weight gain of patients with schizophrenia and bipolar I disorders: a dose ranging randomized trial","volume":"27","author":"Talaei","year":"2016","journal-title":"Turkish Journal of Psychiatry [Turk psikiyatri dergisi]"},{"issue":"573","key":"10.1002\/14651858.CD013337.pub2-BIB0221|cit221","first-page":"1118","article-title":"A comparison on composition of celery, dill and green tea as three medicinal plants with placebo to treat schizophrenic patients' metabolic syndrome","volume":"80","author":"Tavakoli","year":"2014","journal-title":"Afinidad"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881113509904","article-title":"The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study","volume":"28","author":"Taveira","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0000000000000192","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept","volume":"34","author":"Tek","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0224|cit224","first-page":"S181","article-title":"Low-dose naltrexone for antipsychotic-induced weight gain in women with schizophrenia","volume":"19 Suppl 1","author":"Tek","year":"2011","journal-title":"Obesity"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD013337.pub2-BIB0225|cit225","first-page":"283","article-title":"Naltrexone for antipsychotic-induced weight gain in women with schizophrenia","volume":"69","author":"Tek","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0226|cit226","volume-title":"Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia [Dissertation]","author":"Terevnikov","year":"2013"},{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4088\/JCP.v66n0808","article-title":"Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial","volume":"66","author":"Tiihonen","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5B","key":"10.1002\/14651858.CD013337.pub2-BIB0228|cit228","first-page":"840","article-title":"Metformin with life style intervention in treatment of clozapine - induced metabolic disorders","volume":"12","author":"Wang","year":"2009","journal-title":"Chinese General Practice"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0229|cit229","first-page":"252","article-title":"Propofol and etomidate mect combined low-dose aripiprazole in the treatment of schizophrenia control study of 160 cases","volume":"22","author":"Wang","year":"2010","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","article-title":"Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study","volume":"138","author":"Wang","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"67","DOI":"10.9758\/cpn.2020.18.1.67","article-title":"Metformin attenuates liver fat content: finding from schizophrenia patients with olanzapine-induced weight gain","volume":"18","author":"Wang","year":"2020","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12991-020-00319-x","article-title":"Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial","volume":"19","author":"Wang","year":"2020","journal-title":"Annals of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2006.01.008","article-title":"A cognitive\/behavioral group intervention for weight loss in patients treated with atypical antipsychotics","volume":"83","author":"Weber","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4088\/JCP.10m06143gre","article-title":"Buproprion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis","volume":"73","author":"Weiner","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0235|cit235","unstructured":"Liraglutide and the management of overweight and obesity in people with schizophrenia https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2017-004064-35-GB"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0236|cit236","unstructured":"Liraglutide and the management of overweight and obesity in people with schizophrenia https:\/\/www.isrctn.com\/ISRCTN61129760"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double-blind placebo-controlled trial","volume":"26","author":"Whicher","year":"2021","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/s13063-019-3689-5","article-title":"Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial","volume":"20","author":"Whicher","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0239|cit239","first-page":"51","article-title":"Trial design for 'liraglutide and the management of overweight and obesity in people with severe mental illness: A pilot study' in southern health NHS foundation trust","volume":"36 Suppl 1","author":"Whicher","year":"2019","journal-title":"Diabetic Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety","volume":"66","author":"Yagcioglu","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0242|cit242","first-page":"150","article-title":"Effects of 3-months trial of zonisamide and weight management program in obese schizophrenic inpatients","volume":"11 Suppl 1","author":"Bae","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0243|cit243","first-page":"24","article-title":"Add-on sibutramine for olanzapine-induced weight gain","volume":"11","author":"Ginsberg","year":"2004","journal-title":"Primary Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0244|cit244","first-page":"S21","article-title":"Role of metformin versus topiramate in preventing olanzapine associated weight gain and metabolic syndrome","volume":"1","author":"Mondal","year":"2014","journal-title":"Indian Journal of Pharmacology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0245|cit245","unstructured":"Study evaluating the safety, efficacy, and pharmacokinetics of miricorilant in obese adult patients with schizophrenia while taking antipsychotic medications (GRATITUDE II) https:\/\/clinicaltrials.gov\/show\/NCT04524403"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12888-020-02992-4","article-title":"Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle In Antipsychotic users (MELIA) trial","volume":"21","author":"De Boer","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.0045","article-title":"Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents","volume":"17","author":"Aichhorn","year":"2007","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"16","key":"10.1002\/14651858.CD013337.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD013337.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatric Services"},{"issue":"7066","key":"10.1002\/14651858.CD013337.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jimenez","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10401230490453293","article-title":"Atypical antipsychotic induced weight gain: pathophysiology and management","volume":"16","author":"Ananth","year":"2004","journal-title":"Annals of Clinical Psychiatry"},{"issue":"52","key":"10.1002\/14651858.CD013337.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations","volume":"155","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry. Supplement"},{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4239\/wjd.v8.i8.390","article-title":"Prevalence of obesity and diabetes in patients with schizophrenia","volume":"8","author":"Annamalai","year":"2017","journal-title":"World Journal of Diabetes"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0257|cit257","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association (APA)","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2002-36391","article-title":"Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives","volume":"35","author":"Baptista","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10401230309085669","article-title":"Management of weight gain associated with antipsychotics","volume":"15","author":"Birt","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD013337.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0264|cit264","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis","volume":"47","author":"Bora","year":"2017","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S0033291798008186","article-title":"The unhealthy lifestyle of people with schizophrenia","volume":"29","author":"Brown","year":"1999","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2017.11.022","article-title":"Relationship between objectively measured sedentary behavior and health outcomes in schizophrenia patients: the PsychiActive Project","volume":"197","author":"Bueno-Antequera","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0268|cit268","first-page":"4","article-title":"Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65 Suppl 7","author":"Casey","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1039-8562.2003.02054.x","article-title":"Obesity in schizophrenia: what can be done about it?","volume":"12","author":"Catapana","year":"2004","journal-title":"Australasian Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","article-title":"Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome","volume":"49","author":"Cohn","year":"2004","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/070674370104600610","article-title":"Body mass index in persons with schizophrenia","volume":"46","author":"Coodin","year":"2001","journal-title":"Canadian Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013337.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends in Molecular Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013337.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0275|cit275","unstructured":"Chinese Society of Psychiatry (CSP) Chinese Classification of Mental Disorders web.archive.org\/web\/20061205213538\/http:\/\/www.21jk.com\/english\/index.asp"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.nmd.0000100923.20188.2d","article-title":"Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness","volume":"191","author":"Daumit","year":"2003","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.nmd.0000180737.85895.60","article-title":"Physical activity patterns in adults with severe mental illness","volume":"193","author":"Daumit","year":"2005","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0278|cit278","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0279|cit279","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0280|cit280","first-page":"114","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nature\u00a0Reviews\u00a0Endocrinology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13651500510018310","article-title":"Belgian consensus on metabolic problems associated with atypical antipsychotics","volume":"9","author":"De Nayer","year":"2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"Silva","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpsychires.2012.10.005","article-title":"The dietary pattern of patients with schizophrenia: a systematic review","volume":"47","author":"Dipasquale","year":"2013","journal-title":"Journal of Psychiatric Research"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0285|cit285","volume-title":"At Least Five a Week. A report from the Chief Medical Officer","author":"Department of Health","year":"2004"},{"issue":"7109","key":"10.1002\/14651858.CD013337.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0288|cit288","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005148.pub2","article-title":"Interventions to reduce weight gain in schizophrenia","author":"Faulkner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.schres.2006.10.009","article-title":"Body mass index, waist circumference and quality of life in individuals with schizophrenia","volume":"90","author":"Faulkner","year":"2007","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0290|cit290","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"19","key":"10.1002\/14651858.CD013337.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/appi.ajp.2010.09091328","article-title":"The effects of hypertension and body mass index on cognition in schizophrenia","volume":"167","author":"Friedman","year":"2010","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0295|cit295","first-page":"129","article-title":"Fluoxetine: a randomized clinical trial in the treatment of obesity","volume":"18","author":"Goldstein","year":"1994","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0296|cit296","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0163-8343(00)00081-5","article-title":"Weight gain from novel antipsychotic drugs: need for action","volume":"22","author":"Green","year":"2000","journal-title":"General Hospital Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD013337.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pnpbp.2012.01.014","article-title":"Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample","volume":"37","author":"Gurpegui","year":"2012","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0300|cit300","volume-title":"ECDEU assessment manual for psychopharmacology","year":"1976"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD013337.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0304|cit304","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0305|cit305","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"d5422","DOI":"10.1136\/bmj.d5422","article-title":"Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006","volume":"343","author":"Hoang","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","article-title":"Changes in body mass index for individuals with and without schizophrenia","volume":"55","author":"Homel","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"18","key":"10.1002\/14651858.CD013337.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin: new understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013337.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/156720507780362146","article-title":"What can imaging reveal about obesity and the brain?","volume":"4","author":"Jagust","year":"2007","journal-title":"Current Alzheimer Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0312|cit312","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2-3","key":"10.1002\/14651858.CD013337.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2008.07.020","article-title":"Schizophrenia, \"just the facts\": what we know in 2008 Part 3: neurobiology","volume":"106","author":"Keshavan","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2011.01.011","article-title":"Schizophrenia, \"Just the Facts\" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse","volume":"127","author":"Keshavan","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0315|cit315","first-page":"30","article-title":"Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials","volume":"48","author":"Kishi","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0316|cit316","first-page":"32","article-title":"The clinical implications of weight gain in schizophrenia","volume":"62 Suppl 7","author":"Kurzthaler","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2018.02.035","article-title":"Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients","volume":"99","author":"Lappin","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0318|cit318","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2\/chapter-04 10.1002\/9781119536604.ch4"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/003693300104600105","article-title":"Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?","volume":"46","author":"Le Fevre","year":"2001","journal-title":"Scottish Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD013337.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Molecular Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD013337.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.schres.2012.09.019","article-title":"Relationship between metabolic syndrome and cognition in patients with schizophrenia","volume":"142","author":"Lindenmayer","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0325|cit325","first-page":"331","article-title":"Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis","volume":"27","author":"Liu","year":"2015","journal-title":"Shanghai Archives of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0326|cit326","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordhb\/9780199539789.001.0001","volume-title":"The Oxford Handbook of Eye Movements","author":"Liversedge","year":"2011"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-004-1641-y","article-title":"Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study","volume":"48","author":"Mackin","year":"2005","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bmj.317.7161.784","article-title":"Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study","volume":"317","author":"McCreadie","year":"1998","journal-title":"BMJ"},{"issue":"9263","key":"10.1002\/14651858.CD013337.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0331|cit331","first-page":"e1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"7","author":"Moher","journal-title":"PLoS Medicine"},{"issue":"9426","key":"10.1002\/14651858.CD013337.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD013337.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2147\/NDT.S125367","article-title":"Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Okuyama","year":"2016","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/ewjm.175.5.329","article-title":"The poor physical health of people with mental illness","volume":"175","author":"Osborn","year":"2001","journal-title":"Western Journal of Medicine"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7326\/0003-4819-138-1-200301070-00008","article-title":"Obesity in adulthood and its consequences for life expectancy: a life-table analysis","volume":"138","author":"Peeters","year":"2003","journal-title":"Annual of Internal Medicine"},{"issue":"1-3","key":"10.1002\/14651858.CD013337.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","article-title":"Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study","volume":"174","author":"Rajkumar","year":"2017","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1037\/0033-2909.133.5.833","article-title":"Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings","volume":"133","author":"Reichenberg","year":"2007","journal-title":"Psychological Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0342|cit342","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD013337.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0269881117722987","article-title":"Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment","volume":"31","author":"Reynolds","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ps.56.3.324","article-title":"Integrating physical activity into mental health services for persons with serious mental illness","volume":"56","author":"Richardson","year":"2005","journal-title":"Psychiatric services (Washington, D.C.)"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/08039488.2018.1449012","article-title":"Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments","volume":"72","author":"Ringen","year":"2018","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0347|cit347","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/ebmental-2020-300151","article-title":"Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies","volume":"24","author":"Roberts","year":"2021","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v66n0503","article-title":"A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study","volume":"66","author":"Saari","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0350|cit350","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1009013718684","article-title":"Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning","volume":"11","author":"Seaton","year":"2001","journal-title":"Neuropsychology Review"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.3233\/JAD-2011-111073","article-title":"Cognitive function and decline in obesity","volume":"30 Suppl 2","author":"Sellbom","year":"2012","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0353|cit353","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0354|cit354","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0355|cit355","doi-asserted-by":"publisher","first-page":"sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane Schizophrenia Group\u2019s Study-Based Register of Randomized Controlled Trials: development and content analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophrenia Bulletin Open"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0356|cit356","doi-asserted-by":"publisher","DOI":"10.1111\/hir.12366","article-title":"Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis","author":"Shokraneh","year":"2021","journal-title":"Health Information and Libraries Journal"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","article-title":"A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers","volume":"195","author":"Silverman","year":"2018","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1192\/bjp.153.2.214","article-title":"Prevalence of obesity in patients receiving depot antipsychotics","volume":"153","author":"Silverstone","year":"1988","journal-title":"British Journal of Psychiatry"},{"issue":"S212","key":"10.1002\/14651858.CD013337.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"e0156208","DOI":"10.1371\/journal.pone.0156208","article-title":"Metformin for clozapine associated obesity: a systematic review and meta-analysis","volume":"11","author":"Siskind","year":"2016","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0361|cit361","unstructured":"Sterne JA Egger M Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/oxfordjournals.schbul.a007013","article-title":"Nutritional assessment of patients with schizophrenia: a preliminary study","volume":"29","author":"Strassnig","year":"2003","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4088\/JCP.v66n0203","article-title":"Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey","volume":"66","author":"Susce","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013337.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/wps.20458","article-title":"Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis","volume":"16","author":"Vancampfort","year":"2017","journal-title":"World Psychiatry"},{"issue":"9690","key":"10.1002\/14651858.CD013337.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Van Os","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013337.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nyas.13542","article-title":"Updates on obesity pharmacotherapy","volume":"1411","author":"Velazquez","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013337.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.4088\/JCP.13r08657","article-title":"A meta-review of lifestyle interventions for cardiovascular risk factors in the general medical population: lessons for individuals with serious mental illness","volume":"76","author":"Ward","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.282.16.1547","article-title":"Relationship between low cardiorespiratory fitness and mortality in normal weight, overweight and obese men","volume":"282","author":"Wei","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013337.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S2045796017000166","article-title":"Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study","volume":"27","author":"Westman","journal-title":"Epidemiology and Psychiatric Sciences"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0371|cit371","unstructured":"World Health Organization Obesity and overweight fact sheet www.who.int\/mediacentre\/factsheets\/fs311\/en\/"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0372|cit372","unstructured":"World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems 10th Revision icd.who.int\/browse10\/2016\/en"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0373|cit373","first-page":"13","article-title":"Schizophrenia and obesity: impact of antipsychotic medications","volume":"65 Suppl 18","author":"Wirshing","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013337.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD013337.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013337.pub2-BIB0376|cit376","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011127","article-title":"Pharmacological interventions for reducing weight gain in schizophrenia","author":"Hahn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T18:00:40Z","timestamp":1719684040000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013337.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":376,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013337.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}